The GORE® TIGRIS® Vascular Stent goes beyond bare metal with advanced technologies to deliver precise placement and conformability in complex anatomies.

  • On target, every time. Single-handed, precise delivery – 100% of stents deployed within the nominal length.1
  • High-flexion conformability. Lowest straightening force of the ten different stents tested,making it ideal in high-flexion applications.
  • Accuracy with minimal elongation. Average elongation < 0.1% in a U.S.Clinical Study.3
  • Long-term fracture resistance. Zero stent frame fractures at 12 months.1
  • Lasting thromboresistance. Proven CBAS Heparin Surface technology.*


* See full CBAS Heparin Surface references at goremedical.com/cbas

  1. U.S. Food and Drug Administration. Center for Devices and Radiological Health. FDA Summary of Safety and Effectiveness Data. P160004. http://www.accessdata.fda.gov/cdrh_docs/pdf16/P160004B.pdf. Published July 27, 2016. Accessed August 10, 2016.
  2. Data on file. Competitive Comparison Study. February 2015.
  3. Laird JR. Novel nitinol stent for long lesions in the superficial femoral artery and proximal popliteal artery: 24 month results from the TIGRIS Randomized Trial. Presented at VIVA 2016: Vascular Interventional Advances Conference; September 18-22, 2016; Las Vegas, NV.
  4. Supera® Peripheral Stent System [Instructions for Use]. Webster, TX: IDEV Technologies, Inc; 2014.
  5. Data on File. Challenging recirculating human blood loop model.